These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 24798935)

  • 61. Recurrent ovarian cancer: treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience.
    Dear RF; Gao B; Harnett P
    Asia Pac J Clin Oncol; 2010 Mar; 6(1):66-73. PubMed ID: 20398040
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinum-refractory/resistant ovarian cancer.
    Yoshida H; Fujiwara K
    Cancer Med; 2023 Jul; 12(13):14196-14206. PubMed ID: 37184128
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.
    Runnebaum IB; Reichert D; Ringsdorf U; Kuther M; Hesse T; Sehouli J; Wimberger P
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1185-1195. PubMed ID: 29623421
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy and toxicity of gemcitabine and pegylated liposomal Doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer.
    Karaoglu A; Arslan UY; Ozkan M; Kalender ME; Alici S; Coskun U; Gumus M; Celenkoglu G; Er O; Sevinc A; Buyukberber S; Alkis N; Benekli M;
    Asian Pac J Cancer Prev; 2009; 10(1):63-6. PubMed ID: 19469626
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer.
    Richards DA; Loesch D; Vukelja SJ; Wu H; Hyman WJ; Nieves J; Wang Y; Hu S; Shonukan OO; Tai DF
    Invest New Drugs; 2011 Oct; 29(5):963-70. PubMed ID: 20352294
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.
    Gordon AN; Granai CO; Rose PG; Hainsworth J; Lopez A; Weissman C; Rosales R; Sharpington T
    J Clin Oncol; 2000 Sep; 18(17):3093-100. PubMed ID: 10963637
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer.
    Giovinazzo H; Kumar P; Sheikh A; Brooks KM; Ivanovic M; Walsh M; Caron WP; Kowalsky RJ; Song G; Whitlow A; Clarke-Pearson DL; Brewster WR; Van Le L; Zamboni BA; Bae-Jump V; Gehrig PA; Zamboni WC
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):565-73. PubMed ID: 26822231
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.
    Power P; Stuart G; Oza A; Provencher D; Bentley JR; Miller WH; Pouliot JF
    Gynecol Oncol; 2009 Sep; 114(3):410-4. PubMed ID: 19520420
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer.
    Nicoletto MO; Baldoni A; Casarin A; Randon G; Nardin M; Baretta Z; Lardelli P; Nieto A; Alfaro V; Rigamonti C; Conte PF
    Tumori; 2015; 101(5):506-10. PubMed ID: 26108247
    [TBL] [Abstract][Full Text] [Related]  

  • 70. TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.
    Erriquez J; Becco P; Olivero M; Ponzone R; Maggiorotto F; Ferrero A; Scalzo MS; Canuto EM; Sapino A; Verdun di Cantogno L; Bruna P; Aglietta M; Di Renzo MF; Valabrega G
    Gynecol Oncol; 2015 Sep; 138(3):627-33. PubMed ID: 26100858
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
    Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
    Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
    McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
    BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile?
    Lorusso D; Naldini A; Testa A; D'Agostino G; Scambia G; Ferrandina G
    Oncology; 2004; 67(3-4):243-9. PubMed ID: 15557785
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
    Hamanishi J; Takeshima N; Katsumata N; Ushijima K; Kimura T; Takeuchi S; Matsumoto K; Ito K; Mandai M; Nakai H; Sakuragi N; Watari H; Takahashi N; Kato H; Hasegawa K; Yonemori K; Mizuno M; Takehara K; Niikura H; Sawasaki T; Nakao S; Saito T; Enomoto T; Nagase S; Suzuki N; Matsumoto T; Kondo E; Sonoda K; Aihara S; Aoki Y; Okamoto A; Takano H; Kobayashi H; Kato H; Terai Y; Takazawa A; Takahashi Y; Namba Y; Aoki D; Fujiwara K; Sugiyama T; Konishi I
    J Clin Oncol; 2021 Nov; 39(33):3671-3681. PubMed ID: 34473544
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.
    Steppan I; Reimer D; Sevelda U; Ulmer H; Marth C; Zeimet AG
    Chemotherapy; 2009; 55(6):391-8. PubMed ID: 19955744
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial.
    Wang T; Tang J; Yang H; Yin R; Zhang J; Zhou Q; Liu Z; Cao L; Li L; Huang Y; Jiang K; Wang W; She F; Guan N; Hou Z; Li N; Wu L
    JAMA Oncol; 2022 Aug; 8(8):1169-1176. PubMed ID: 35771546
    [TBL] [Abstract][Full Text] [Related]  

  • 77. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.
    Safra T; Borgato L; Nicoletto MO; Rolnitzky L; Pelles-Avraham S; Geva R; Donach ME; Curtin J; Novetsky A; Grenader T; Lai WC; Gabizon A; Boyd L; Muggia F
    Mol Cancer Ther; 2011 Oct; 10(10):2000-7. PubMed ID: 21835933
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Phase I study on pegylated liposomal doxorubicin in combination with docetaxel for patients with platinum-resistant or partially platinum-sensitive epithelial ovarian cancer: The Kansai Clinical Oncology Group study.
    Hori K; Ito K; Kuritani K; Kuji S; Furukawa N; Tsubamoto H; Arakawa A
    J Cancer Res Ther; 2019; 15(6):1201-1206. PubMed ID: 31898647
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
    Tas F; Guney N; Derin D; Aydiner A; Topuz E
    Int J Clin Oncol; 2008 Apr; 13(2):156-60. PubMed ID: 18463961
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
    Comella P; Biglietto M; Casaretti R; De Lucia L; Avallone A; Maiorino L; Di Lullo L; De Cataldis G; Rivellini F; Comella G
    Oncology; 2001; 60(2):127-33. PubMed ID: 11244327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.